glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
The original capital of the islands was at Port Louis to the north of the present site of Stanley, on Berkeley Sound. Captains Francis Crozier and James Clark Ross were recruited by Governor Richard Moody in his quest to find a new capital for The Falklands. Both Crozier and Ross (who are remembered in Crozier Place and Ross Road in Stanley) were among the Royal Navy's most distinguished seafarers. They spent five months in the islands with their ships Terror and Erebus, later lost looking for the Northwest Passage. Governor Moody (after whom Moody Brook is named), however, decided to move the capital to Port Jackson, which was renamed "Stanley Harbour", after a survey. Stanley Harbour was considered to have a deeper anchorage for visiting ships. Not all the inhabitants were happy with the change; a JW Whitington is recorded as saying, "Of all the miserable bog holes, I believe that Mr Moody has selected one of the worst for the site of his town."
==== Adenoma of the adrenal gland ==== Adrenal adenomas are benign tumors of the adrenal gland. In most cases, the tumors display no symptoms and require no treatment. In rare cases, however, some adrenal adenomas may become activated. When activated, the adenoma begins to produce hormones in much larger quantities than what the adrenal glands would normally produce, leading to health complications including primary aldosteronism and hyperandrogenism.
Marguerite Yourcenar (UK: , US: ; French: [maʁɡ(ə)ʁit juʁsənaʁ] ; born Marguerite Antoinette Jeanne Marie Ghislaine Cleenewerck de Crayencour; 8 June 1903 – 17 December 1987) was a Belgian-born French novelist and essayist who became a US citizen in 1947. Winner of the Prix Femina and the Erasmus Prize, she was the first woman elected to the Académie Française, in 1980. In 1965, she was nominated for the Nobel Prize in Literature.
The exception to this rule is crocodiles, which have a four-chambered heart. In the heart of lungfish, the septum extends partway into the ventricle. This allows for some degree of separation between the de-oxygenated bloodstream destined for the lungs and the oxygenated stream that is delivered to the rest of the body. The absence of such a division in living amphibian species may be partly due to the amount of respiration that occurs through the skin; thus, the blood returned to the heart through the venae cavae is already partially oxygenated. As a result, there may be less need for a finer division between the two bloodstreams than in lungfish or other tetrapods. Nonetheless, in at least some species of amphibian, the spongy nature of the ventricle does seem to maintain more of a separation between the bloodstreams. Also, the original valves of the conus arteriosus have been replaced by a spiral valve that divides it into two parallel parts, thereby helping to keep the two bloodstreams separate.
Sources: en.wikipedia.org
is constant throughout the change. Additionally, the Rahemi–Li model links the temperature dependence of Young’s modulus in metals to changes in the electron work function, providing a theoretical basis using a generalized Lennard-Jones potential.
In October 2020, the company acquired GlobalCare, a mobile nursing and ambulant care company with operations in more than 65 countries, and snapIoT, a company that provides a digitized clinical platform that supports remote participation in clinical trials. In June 2021, the company changed its name to Labcorp Drug Development. In February 2023, the company was renamed Fortrea Holdings. In July 2023, Labcorp completed the corporate spin-off of the company. In June 2024, the company sold its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners.
After the riots, the controversial New Economic Policy was launched by Prime Minister Tun Abdul Razak, trying to increase the share of the economy held by the bumiputera. Under Prime Minister Mahathir Mohamad there was a period of rapid economic growth and urbanisation beginning in the 1980s. The economy shifted from being agriculturally based to one based on manufacturing and industry. Numerous mega-projects were completed, such as the Petronas Towers, the North–South Expressway, the Multimedia Super Corridor, and the new federal administrative capital of Putrajaya. In the late 1990s, the Asian financial crisis impacted the country, nearly causing their currency, stock, and property markets to crash; however, they later recovered. The 1MDB scandal was a major global corruption scandal that implicated then-Prime Minister Najib Razak in 2015. The scandal contributed to the first change in the ruling political party since independence in the 2018 general election. In the 2020s, the country was gripped by a political crisis that coincided with health and economic crises caused by the COVID-19 pandemic. This was then followed by an earlier general election in November 2022, which resulted in the first hung parliament in the nation's history. On 24 November 2022, Anwar Ibrahim was sworn in as the 10th Prime Minister of Malaysia, leading a grand coalition government.
Catulle Mendès adapted Medea into his play Medée in 1898, in three acts and in verse. Alfons Mucha drew a poster for a performance of this play starring Sarah Bernhardt. Jean Anouilh adapted the Medea story in his French drama Médée in 1946. Robinson Jeffers adapted Medea into a hit Broadway play in 1947, in a famous production starring Judith Anderson, the first of three actresses to win a Tony Award for the role. It was directed by John Gielgud, who co-starred as Jason. Medea opened on Broadway at the National Theatre on 20 October 1947, transferred to the Royale Theatre on 15 December, and closed on 15 May 1948, after 214 performances. At the 2nd Tony Awards on 28 March 1948, Judith Anderson shared (with Katharine Cornell and Jessica Tandy) the Award for Best Actress in a Play. Another staging, produced and directed by Guthrie McClintic at the City Center, premiered on 2 May 1949, and closed, after 16 performances, on 21 May. A staging in 1982, at the Cort Theatre, brought a Tony win for Zoe Caldwell, who played Medea, and a Best Featured Actress in a Play nomination for Judith Anderson as Nurse. With a subsequent Tony win for Diana Rigg in 1994, the play holds the American Theatre Wing's Tony Award record for most wins for the same female lead character in a play. Ben Bagley's Shoestring Revue performed a musical parody off-Broadway in the 1950s which was later issued on an LP and a CD, and was revived in 1995. The same plot points take place, but Medea in Disneyland is a parody, in that it takes place in a Walt Disney animated cartoon.
The deal also stated that Israel would retain "complete military freedom of action" to attack Lebanon in the event of a violation of the agreement by Hezbollah or another entity in Lebanon. Prime Minister of Lebanon Najib Mikati issued strong support for the agreement and urged the international community to help implement the agreement immediately in order to "halt Israeli aggression". On 27 November, thousands of displaced Lebanese began to return to areas ruined by Israeli strikes.
Sources: en.wikipedia.org
The Green Chemistry Institute (GCI) supports the "implementation of green chemistry and engineering throughout the global chemistry enterprise." The GCI organizes an annual conference, the Green Chemistry and Engineering Conference, provides research grants, administers awards, and provides information and support for green chemistry practices to educators, researchers, and industry. The GCI was founded in 1997 as an independent non-profit organization, by chemists Joe Breen and Dennis Hjeresen in cooperation with the Environmental Protection Agency. In 2001, the GCI became a part of the American Chemical Society.[1]
=== Nexon === In August 2014, Nexon announced Counter-Strike Nexon: Zombies, a free-to-play, zombie-themed spin-off, developed on the GoldSrc game engine. On September 23, 2014, an open beta was released on Steam. The game launched on October 7, 2014, featuring 50 maps and 20 game modes. The game features both player versus player modes such as team deathmatch, hostage rescue, and bomb defusal, alongside player versus environment modes such as cooperative campaign missions and base defending. Reception from critics was generally negative, with criticism aimed at the game's poor user interface, microtransactions, and dated graphics. On October 30, 2019, Counter-Strike Nexon: Zombies was renamed to Counter-Strike Nexon: Studio. On August 21, 2024, Counter-Strike Nexon: Studio was renamed to Counter-Strike Nexon. The game is set to be shut-down on September 30, 2026.
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. It is used when dietary changes, exercise, and weight loss are not enough. It is taken by mouth. Side effect may include low blood sugar, vomiting, abdominal pain, rash, and liver problems. Use by those with significant kidney problems or liver problems or who are pregnant is not recommended. Gliclazide is in the sulfonylurea family of medications. It works mostly by increasing the release of insulin. Gliclazide was patented in 1966 and approved for medical use in 1972. It is on the World Health Organization's List of Essential Medicines. It is not available for sale in the United States.
In the United States, it is against federal regulations for supplement manufacturers to claim that their products prevent or treat any disease. Companies are allowed to use what is referred to as "Structure/Function" wording if there is substantiation of scientific evidence for a supplement providing a potential health effect. An example would be "_____ helps maintain healthy joints", but the label must bear a disclaimer that the Food and Drug Administration (FDA) "has not evaluated the claim" and that the dietary supplement product is not intended to "diagnose, treat, cure or prevent any disease", because only a medication can legally make such a claim. The FDA enforces these regulations as well as prohibiting the sale of supplements and supplement ingredients that are dangerous, or supplements not made according to standardized good manufacturing practices (GMPs). The European Commission has established harmonized rules to help insure that food supplements in the European Union are safe and appropriately labeled.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.